Women with Rare Subtype of Ovarian Cancer Could Benefit from Hormone Therapy

Women with Rare Subtype of Ovarian Cancer Could Benefit from Hormone Therapy
Women with low-grade serous carcinoma (LGSC), a rare subtype of epithelial ovarian or peritoneum cancer, are more likely to survive when treated with hormonal therapy after surgery and chemotherapy, new research suggests. In the study, hormonal maintenance therapy following surgery and platinum-based chemotherapy more than doubled the time to disease progression compared with routine observation. Overall survival

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *